Penn, CHOP Researchers Find Less-Used Regimen Is More Effective for HIV-Infected Children

facebook twitter google print email
Media Contact:Steve Graff | stephen.graff@uphs.upenn.edu | 215-349-5653April 30, 2013

Researchers from The Children’s Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, along with colleagues at the Botswana-Baylor Children's Clinical Centre of Excellence, conducted the first large-scale comparison of first-line treatments for HIV-positive children, finding that initial treatment with efavirenz was more effective than nevirapine in suppressing the virus in children ages 3 to 16. However, the less effective nevirapine is currently used much more often in countries with a high prevalence of HIV. The results of the study of more than 800 children are published today in the Journal of the American Medical Association (JAMA).

There are more than 3 million HIV-positive children in the world, and more than 90 percent of them live in sub-Saharan Africa. Currently, the World Health Organization (WHO) recommends both efavirenz and nevirapine for first-line pediatric use in resource-limited settings such as sub-Saharan Africa. Lead author Elizabeth Lowenthal, MD, MSCE of The Children’s Hospital of Philadelphia, says this study has the potential to change the standard of care in the parts of the world where most HIV-infected children live.

“Because nevirapine costs less than efavirenz and is more widely available in pediatric formulations, it is currently the more frequent choice for initial treatment in these children. However, our study suggests that efavirenz produces better outcomes,” said Dr. Lowenthal.

Senior author Robert Gross, MD, MSCE, an associate professor of Infectious Dis eases and Epidemiology at Penn Medicine, adds, “Given this evidence, it is very reasonable to adjust pediatric HIV treatment guidelines. However, as we move towards such changes, more work should be done to make efavirenz a more financially viable option for children on anti-retroviral therapy in these resource-limited settings.”

Click here to view the full release.

Multimedia